Abstract
Tumor response is strongly enhanced by addition of tumor necrosis factor (TNF)-α to chemotherapy in localregional perfusion. TNF primarily targets the endothelial lining of the tumor-associated vasculature, thereby improving permeability of the vascular bed. This augments uptake of the coadministered chemotherapeutic drug in the tumor. In vitro, however the high dose of TNF did not directly affect endothelial cells, indicating that other factors, most likely TNF-induced, are involved in the antivascular activities observed in vivo. This is supported by in vivo studies in our laboratory in which depletion of leukocytes resulted in loss of the antivascular activity of TNF. The present study examined the role of peripheral blood mononuclear cells (PBMCs) on endothelial cells by exposing them to TNF, interferon (IFN)-γ, and PBMCs. We observed morphological changes of the endothelial cells when exposed to TNF in combination with IFN. Endothelial cells became elongated. and gaps between the cells formed. Addition of PBMCs enhanced these alterations. The endothelial layer became disrupted with highly irregular-shaped cells displaying large gap formations. PBMCs also contributed to an increased permeability of the endothelial layer without augmenting apoptosis. Replacing PBMC by interleukin (IL)-1β produced similar effect with regard to inhibition of cell growth, morphological changes, and induction of apoptosis. Blocking IL-1β with a neutralizing antibody diminished the effects inflicted of PBMCs. These observations indicate that endogenously produced IL-1β by primed PBMCs plays an important role in the antivascular effect of TNF.
Similar content being viewed by others
References
Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., and Lejeune, F. J. (1992) High-dose recombinant tumor necrosis factor α in combination with interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10, 52–60.
Eggermont, A.M.M., Schraffordt Koops, H., Lienard, D., et al. (1996) Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol. 14, 2653–2665.
Eggermont, A.M.M. (2000) TNF registered in Europe: does TNF get a second chance?. J. Immunother. 23, 505–506.
de Wilt, J.H.W., ten Hagen, T.L.M., de Boeck, G., van Tiel, S. T., De Bruijn, E. A. and Eggermont, A.M.M. (2000) Tumour necrosis factor α increases melphalan concentration in tumour tissue after isolated limb perfusion. Br. J. Cancer 82, 1000–10003.
Van Der Veen A. H., de Wilt, J.H.W., Eggermont, A.M.M., van Tiel, S. T., Seynhaeve, A.L.B., and ten Hagen, T.L.M. (2000) TNF-α augments intratumoural concentrations of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br. J. Cancer 82, 973–980.
Brouckaert, P., Takahashi, N., van Tiel, S. T., et al. (2004) Tumor necrosis factor-α augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int. J. Cancer 109, 442–448.
ten Hagen, T.L.M., Van Der Veen, A. H., Nooijen, P. T., van Tiel, S. T., Seynhaeve, A.L.B., and Eggermont, A.M.M. (2000) Low-dose tumor necrosis factor-α augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int. J. Cancer 87, 829–837.
ten Hagen, T.L.M. and Eggermont, A.M.M. (2002) Manipulation of the tumour-associated vasculature to improve tumour therapy. J. Liposome Res. 12, 149–154.
Lejeune, F. J., Ruegg, C., and Lienard, D. (1998) Clinical applications of TNF-α in cancer. Curr. Opin. Immunol. 10, 573–580.
Nooijen, P. T., Manusama, E. R., Eggermont, A.M.M., et al. (1996) Synergistic effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br. J. Cancer 74, 1908–1915.
Mauerhoff, T., Belfiore, A., Pujol-Borrell, R., and Bottazzo, G. F. (1994) Growth inhibition of human endothelial cells by human recombinant tumor necrosis factor α and −γ. Tumori 80, 301–305.
Norioka, K., Borden, E. C., and Auerbach, R. (1992) Inhibitory effects of cytokines on vascular endothelial cells: synergistic interactions among-gamma, tumor necrosis factor-α, and interleukin-1. J. Immunother. 12, 13–18.
Burke-Gaffney, A. and Keenan, A. K. (1993) Does TNF-α directly increase endothelial cell monolayer permeability? Agents Actions 38, C83-C85.
Ruegg, C., Yilmaz, A., Bieler, G., Bamat, J., Chaubert, P., and Lejeune, F. J. (1998) Evidence for the involvement of endothelial cell integrin αVβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat. Med. 4, 408–414.
Korpelainen, E. I., Gamble, J. R., Smith, W. B., et al. (1993) The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor α and potentiates interleukin 8 secretion and neutrophil transmigration. Proc. Natl. Acad. Sci. USA 90 11,137–11,141.
Luu, N. T., Rainger, G. E., and Nash, G. B. (1999) Kinetics of the different steps during neutrophil migration through cultured endothelial monolayers treated with tumour necrosis factor-α. J. Vasc. Res. 36, 477–485.
Yilmaz, A., Bieler, G., Spertini, O., Lejeune, F. J., and Ruegg, C. (1998) Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon-γ results in simultaneous synergistic and reversible effects on proliferation and morphology. Int. J. Cancer 77, 592–599.
Manusama, E. R., Nooijen, P. T., Stavast, J., de Wilt, J.H.W., Marquet, R.L., and Eggermont, A.M.M. (1998) Assessment of the role of neutrophils on the antitumor effect of TNFα in an in vivo isolated limb perfusion model in sarcomabearing brown Norway rats. J. Surg. Res. 78, 169–175.
Kramer, S. M. and Carver, M. E. (1986) Serum-free in vitro bioassay for the detection of tumor necrosis factor. J. Immunol. Methods. 93, 201–206.
Jaffe, E. A., Nachman, R. L., Becker, C. G., and Minick, C. R. (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Investig. 52, 2745–2756.
Skehan, P., Storeng, R., Scudiero, D., et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer. Inst. 82, 1107–1112.
Takahashi, N., Fiers, W., and Brouckaert, P. (1995) Antitumor activity of tumor necrosis factor in combination with interferon-γ is not affected by prior tolerization. Int. J. Cancer 63, 846–854.
van Ijken, M. G., van Etten, B., de Wilt, J.H.W., van Tiel, S.T., ten Hagen, T.L.M., and Eggermont, A.M.M. (2000) Tumor necrosis factor-α augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J. Immunother. 23, 449–455.
Schnittler, H. J., Schneider, S. W., Raifer, H., et al. (2001) Role of actin filaments in endothelial cell-cell adhesion and membrane stability under fluid shear stress. Pflugers Arch. 442, 675–687.
Gao, B., Saba, T. M., and Tsan, M. F. (2002) Role of α(v)β(3)-integrin in TNF-α-induced endothelial cell migration. Am. J. Physiol. 283 C1196-C1205.
Lim, M. J., Chiang, E. T., Hechtman, H. B., and Shepro, D. (2001) Inflammation-induced subcellular redistribution of VE-cadherin, actin, and γ-catenin in cultured human lung microvessel endothelial cells. Microvasc. Res. 62, 366–382.
Goldblum, S. E., Ding, X., and Campbell-Washington, J. (1993) TNF-α induces endothelial cell F-actin depolymerization, new actin synthesis, and barrier dysfunction. Am. J. Physiol. 264, C894-C905.
Kohno, K., Hamanaka, R., Abe, T., et al. (1993) Morphological change and destabilization of β-actin mRNA by tumor/necrosis factor in human microvascular endothelial cells. Exp. Cell. Res. 208, 498–503.
Coyne, C. B., Vanhook, M. K., Gambling, T. M., Carson, J. L., Boucher, R. C., and Johnson, L. G. (2002) Regulation of airway tight junctions by proinflammatory cytokines. Mol. Biol. Cell. 13, 3218–3234.
Wachtel, M., Bolliger, M. F., Ishihara, H., Frei, K., Bluethmann, H., and Gloor, S. M. (2001) Down-regulation of occludin expression in astrocytes by tumour necrosis factor (TNF) is mediated via TNF type-1 receptor and nuclear factor-kB activation. J. Neurochem. 78 155–162.
Mankertz, J., Tavalali, S., Schmitz, H., et al. (2000) Expression from the human occludin promoter is affected by tumor necrosis factor α and interferon γ. J. Cell Sci. 113, 2085–2090.
Kniesel, U. and Wolburg, H. (2000) Tight junctions of the blood-brain barrier. Cell. Mol. Neurobiol. 20, 57–76.
Wright, T. J., Leach, L., Shaw, P. E., and Jones, P. (2002) Dynamics of vascular endothelial-cadherin and β-catenin localization by vascular endothelial growth factor-induced angiogenesis in human umbilical vein cells. Exp. Cell Res. 280, 159–168.
Friedl, J., Puhlmann, M., Bartlett, D. L., et al. (2002) Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood 100, 1334–1339.
Nooteboom, A., van der Linden, C. J., and Hendriks, T. (2002) Tumor necrosis factor-α and interleukin-1β mediate endothelial permeability induced by lipopolysaccharide-stimulated whole blood. Crit. Care Med. 30, 2063–2068.
Petrache, I., Birukova, A., Ramirez, S. I., Garcia, J. G., and Verin, A. D. (2003) The role of the microtubules in tumor necrosis factor-{α}-induced endothelial cell permeability. Am. J. Respir. Cell Mol. Biol. 28, 574–581.
Dvorak, A. M. and Feng, D. (2001) The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J. Histochem. Cytochem. 49, 419–432.
Brunstein, F., Hoving, S., Seynhaeve, A.L.B., et al. (2004) Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J. Natl. Cancer Inst. 96, 1603–1610.
Ahlberg, R., MacNamara, B., Andersson, M. et al. (2003) Stimulation of T-cell cytokine production and NK-cell function by IL-2, IFN-α and histamine treatment during remission of non-Hodgkin's lymphoma. Hematol. J. 4, 336–341.
Andersson, U., Andersson, J., Lindfors, A., Wagner, K., Moller, G., and Heusser, C. H. (1990) Simultaneous production of interleukin 2, interleukin 4 and interferon-γ by activated human blood lymphocytes. Eur. J. Immunol. 20, 1591–1596.
Luo, Y., Chen, X., and O'Donnell, M. A. (2003) Role of Th1 and Th2 cytokines in BCG-induced IFN-γ production: cytokine promotion and simulation of BCG effect cytokine. Cytokine 21, 17–26.
Nilsen, E. M., Johansen, F. E., Jahnsen, F. L., et al. (1998) Cytokine profiles of cultured microvascular endothelial cells from the human intestine. Gut 42, 635–642.
Renard, N., Lienard, D., Lespagnard, L., Eggermont, A.M.M., Heimann, R., and Lejeune, F. J. (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor α (rTNFα). Int. J. Cancer 57, 656–663.
Ramesh, R., Marrogi, A. J., Munshi, A., Abboud, C. N., and Freeman, S. M. (1996) In vivo analysis of the ‘bystander effect’: a cytokine cascade. Exp. Hematol. 24, 829–838.
Barth, R. J., Jr., Mule, J. J., Spiess, P. J., and Rosenberg, S. A. (1991) interferon γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+tumor-infiltrating lymphocytes. J. Exp. Med. 173, 647–658.
Sadanaga, N., Nagoshi, M., Lederer, J. A., Joo, H. G., Eberlein, T. J., and Goedegebuure, P. S. (1999) Local secretion of IFN-γ induces an antitumor response: comparison between T cells plus IL-2 and IFN-γ transfected tumor cells. J. Immunother. 22, 315–323.
Eggermont, A.M.M., de Wilt, J. H., and ten Hagen, T.L.M. (2003) Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 4, 429–437.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Seynhaeve, A.L.B., Vermeulen, C.E., Eggermont, A.M.M. et al. Cytokines and vascular permeability. Cell Biochem Biophys 44, 157–169 (2006). https://doi.org/10.1385/CBB:44:1:157
Issue Date:
DOI: https://doi.org/10.1385/CBB:44:1:157